Ask AI
Targeted Agents in Relapsed ES SCLC

CE / CME

Translating Evidence to Action in Relapsed ES-SCLC: Integrating New Targeted Agents Into Clinical Practice

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: November 25, 2025

Expiration: May 24, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086-2092.
  2. Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645-654.
  3. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393:349-361.
  4. Lurbinectedin [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals; 2025.
  5. Paz-Ares LG, Gonzalez AF, Navarro A, et al. Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): results from a phase 2 expansion cohort. Presented at: American Society of Clinical Oncology Congress; May 31-June 4, 2024. Abstract 8094.
  6. Besse B, Paz-Ares LG, Peters S, et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). Presented at: American Society of Clinical Oncology Congress; June 2-6, 2023. Abstract TPS8613.
  7. Calles A, Navarro A, Doger de Speville Uribe BG, et al. Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study. J Thorac Oncol. 2025;20(7):969-982.
  8. Aix SP, Navarro A, Olmedo Garcia ME, et al. Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: results of the 2SMALL phase 1/2 study (NCT04253145). Presented at: American Society of Clinical Oncology Congress; May 30-June 3, 2025. Abstract 8013.
  9. Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66.
  10. Su PL, Chakravarthy K, Furuya N, et al. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Molecular Cancer. 2024;23(1).
  11. Ahn M, Byoung Chul Cho, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063-2075.
  12. ‌Sands J, Cho BC, Ahn MJ, et al. Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up. Presented at: World Conference on Lung Cancer; September 7-10, 2024. Abstract OA10.03.
  13. Paulson KG, Lau SCM, Ahn MJ, et al. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025;26:1300-1311.
  14. Wermke M, Gambardella V, Kuboki Y, et al. Phase I dose-escalation results for the delta-like ligand 3/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. J Clin Oncol. 2025;43:3021-3031.
  15. Rudin CM, Mountzios G, Sun L, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025;393:1138-1150
  16. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658-667.
  17. Riccardi F, Dal Bo M, Macor P, Toffoli G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front Pharmacol. 2023;14:1274088.
  18. Chandana SR, Choudhury NJ, Dowlat A, et al. First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Presented at: American Society of Clinical Oncology Congress; May 31-June 4, 2024. Abstract 3001.
  19. Morgensztern D, Ready N, Johnson ML, et al. A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer. Clin Cancer Res. 2024;30:5042-5052.
  20. Patel MR, Hong DS, Hu X, et al. ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update. J Clin Oncol. 2025;43:3041.
  21. Ahn MJ, Johnson ML, Paz-Ares L, et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: primary analysis of the phase 2 IDeate-Lung 01 study. Presented at: World Conference on Lung Cancer; September 6-9, 2025. Abstract OA06.03.
  22. Rudin CM, Ahn MJ, Johnson M, et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of Ideate-lung01. Presented at: World Conference on Lung Cancer; September 7-10, 2024. Abstract OA04.03.
  23. Owonikoko TK, Byers LA, Cheng Y, et al. IDeate-Lung02: a phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC). Presented at: American Society of Clinical Oncology Congress; May 31-June 4, 2024. Abstract TPS8126.
  24. Byers LA, Cho BC, Cooper AJ, et al. Safety and efficacy of ABBV-706, a seizure-related homolog protein 6–targeting antibody-drug conjugate, in R/R SCLC. Presented at: World Conference on Lung Cancer; September 6-9, 2025. Abstract OA06.04.